Sirion Therapeutics Receives NDA Acceptance And Priority Review From The FDA For Durezol(TM) In The Treatment Of ... (Medical News Today)
Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced that its New Drug Application (NDA) for Durezol(TM) has been accepted by the U.S. Food and Drug Administration (FDA) and granted priority review. Sirion Therapeutics is seeking approval from the FDA for its investigational compound Durezol(TM) (difluprednate ophthalmic emulsion) 0.

Boston Scientific gets 3 new FDA approvals (BizJournals)
Boston Scientific Corp. has a shot of good news this week with three separate federal regulatory approvals of its products. (BSX)

Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business (The San Francisco Examiner)
NATICK, Mass. ( Map ) - NATICK, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced U.S. Food and Drug Administration (FDA) approval for three products in its Cardiac Rhythm Management business.